IFN-β treatment requires B cells for efficacy in neuroautoimmunity

Journal of Immunology

Volumn 194, Issue 5, 2015, Pages 2110-2116

  Schubert, Ryan D ^a,b   Hu, Yang ^c   Kumar, Gaurav ^c   Szeto, Spencer ^c   Abraham, Peter ^a   Winderl, Johannes ^a   Guthridge, Joel M ^c   Pardo, Gabriel ^c   Dunn, Jeffrey ^a   Steinman, Lawrence ^a   Axtell, Robert C ^c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BETA INTERFERON; CD19 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; IL10 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; MEMORY CELL; MOUSE; MULTIPLE SCLEROSIS; NEUROAUTOIMMUNITY; NONHUMAN; PHENOTYPE; PLASMABLAST; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; SPLEEN CELL; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; BRAIN; CASE-CONTROL STUDIES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; GLATIRAMER ACETATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; INTERLEUKIN-10; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; PEPTIDES; SIGNAL TRANSDUCTION; SPLEEN;

EID: 84924362998     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402029     Document Type: Article

References (28)

1. Feng, X., N. P. Reder, M. Yanamandala, A. Hill, B. S. Franek, T. B. Niewold, A. T. Reder, and A. Javed. 2012. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J. Neurol. Sci. 313: 48-53.
2. Kiefer, K., M. A. Oropallo, M. P. Cancro, and A. Marshak-Rothstein. 2012. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell Biol. 90: 498-504.
3. Palace, J., M. I. Leite, A. Nairne, and A. Vincent. 2010. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67: 1016-1017.
4. Krumbholz, M., H. Faber, F. Steinmeyer, L. A. Hoffmann, T. Kümpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al. 2008. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463.
5. Zanotti, C., M. Chiarini, F. Serana, R. Capra, M. Rottoli, M. Rovaris, G. Cavaletti, R. Clerici, M. Rezzonico, L. Caimi, and L. Imberti. 2011. Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients. J. Neuroimmunol. 240-241: 147-150.
6. Panitch, H., D. Goodin, G. Francis, P. Chang, P. Coyle, P. O'Connor, D. Li, and B. Weinshenker, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. 2005. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J. Neurol. Sci. 239: 67-74.
7. Liu, Y., R. Carlsson, M. Comabella, J. Wang, M. Kosicki, B. Carrion, M. Hasan, X. Wu, X. Montalban, M. H. Dziegiel, et al. 2014. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 20: 272-282.
8. Prinz, M., H. Schmidt, A. Mildner, K. P. Knobeloch, U. K. Hanisch, J. Raasch, D. Merkler, C. Detje, I. Gutcher, J. Mages, et al. 2008. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28: 675-686.
9. Kalled, S. L. 2006. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18: 290-296.
10. Blair, P. A., L. Y. Noreña, F. Flores-Borja, D. J. Rawlings, D. A. Isenberg, M. R. Ehrenstein, and C. Mauri. 2010. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32: 129-140.
11. Avery, D. T., J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye. 2005. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 174: 4034-4042.
12. Maseda, D., S. H. Smith, D. J. DiLillo, J. M. Bryant, K. M. Candando, C. T.Weaver, and T. F. Tedder. 2012. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J. Immunol. 188: 1036-1048.
13. Matsushita, T., M. Fujimoto, M. Hasegawa, K. Komura, K. Takehara, T. F. Tedder, and S. Sato. 2006. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol. 168: 812-821.
14. Yoshizaki, A., T. Miyagaki, D. J. DiLillo, T. Matsushita, M. Horikawa, E. I. Kountikov, R. Spolski, J. C. Poe, W. J. Leonard, and T. F. Tedder. 2012. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491: 264-268.
15. Galicia, G., B. Boulianne, N. Pikor, A.Martin, and J. L. Gommerman. 2013. Secondary B cell receptor diversification is necessary for T cell mediated neuro-inflammation during experimental autoimmune encephalomyelitis. PLoS ONE 8: e61478.
16. Landolt-Marticorena, C., R. Wither, H. Reich, A. Herzenberg, J. Scholey, D. D. Gladman, M. B. Urowitz, P. R. Fortin, and J. Wither. 2011. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J. Rheumatol. 38: 642-651.
17. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
18. Zhang, X., E. Deriaud, X. Jiao, D. Braun, C. Leclerc, and R. Lo-Man. 2007. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J. Exp. Med. 204: 1107-1118.
19. Kitamura, D., J. Roes, R. Kühn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350: 423-426.
20. Watanabe, R., N. Ishiura, H. Nakashima, Y. Kuwano, H. Okochi, K. Tamaki, S. Sato, T. F. Tedder, and M. Fujimoto. 2010. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184: 4801-4809.
21. Furie, R., M. Petri, O. Zamani, R. Cervera, D. J. Wallace, D. Tegzová, J. Sanchez-Guerrero, A. Schwarting, J. T. Merrill, W. W. Chatham, et al BLISS- 76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63: 3918-3930.
22. Isenberg, D., C. Gordon, D. Licu, S. Copt, C. P. Rossi, and D. Wofsy. 2014. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. DOI: 10.1136/annrheumdis-2013-205067.
23. Kappos, L., H. P. Hartung, M. S. Freedman, A. Boyko, E. W. Radü, D. D. Mikol, M. Lamarine, Y. Hyvert, U. Freudensprung, T. Plitz, and J. van Beek, ATAMS Study Group. 2014. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13: 353-363.
24. Krumbholz, M., T. Derfuss, R. Hohlfeld, and E. Meinl. 2012. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8: 613-623.
25. Scapini, P., Y. Hu, C. L. Chu, T. S. Migone, A. L. Defranco, M. A. Cassatella, and C. A. Lowell. 2010. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J. Exp. Med. 207: 1757-1773.
26. Scapini, P., B. Nardelli, G. Nadali, F. Calzetti, G. Pizzolo, C. Montecucco, and M. A. Cassatella. 2003. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 197: 297-302.
27. Rickert, R. C., J. Jellusova, and A. V. Miletic. 2011. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244: 115-133.
28. Palanichamy, A., J. Barnard, B. Zheng, T. Owen, T. Quach, C. Wei, R. J. Looney, I. Sanz, and J. H. Anolik. 2009. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182: 5982-5993.